ML-SYS / 2026.07NON-CLINICAL RESEARCH MATERIALSORIGIN DECLARED BY LOT

← Compound index

RM-END / Endocrine and peptide-hormone analogs

Leuprolide

Also known as: Leuprorelin · Leuprolide acetate · GnRH agonist

Approved comparator exists

Grade describes the published research on the molecule. It is not a quality score, a safety score, or a release state.

What this is

Leuprolide is a GnRH agonist peptide. Salt, concentration and delivery system—especially depot microsphere formulations—are material parts of the product record.

Evidence position

FDA-labeled comparators and randomized studies support Grade A for defined finished products.

What the record does not establish

That evidence cannot be used to treat a raw peptide, a different salt or an unverified depot as equivalent.

Sources

  • 01
    Lupron Depot prescribing informationDailyMed / U.S. National Library of Medicine
    Shows
    Current U.S. depot-product label and release-duration distinctions
    Does not show
    A depot label does not describe loose peptide or another formulation
  • 02
    Degarelix versus leuprolide randomized trialPubMed
    Shows
    Randomized human comparator data involving a labeled leuprolide presentation
    Does not show
    Clinical protocol evidence, not third-party material verification

External database index

LIVE DATABASE INDEX / SEPARATE FROM CURATED EVIDENCE

Records below come directly from public scientific databases. They help find relevant material, but do not affect the evidence grade until they are matched to the molecule and added to the curated source list.

PUBMED / FOUND RECORDS

  1. Improved Outcomes with Enzalutamide in Biochemically Recurrent Prostate Cancer.The New England journal of medicine / 2023 Oct 19PMID 37851874 / DOI 10.1056/NEJMoa2303974
  2. Oral Relugolix for Androgen-Deprivation Therapy in Advanced Prostate Cancer.The New England journal of medicine / 2020 Jun 4PMID 32469183 / DOI 10.1056/NEJMoa2004325
  3. Leuprolide. / 2012PMID 31643987
  4. Improved Survival with Enzalutamide in Biochemically Recurrent Prostate Cancer.The New England journal of medicine / 2026 Feb 5PMID 41124201 / DOI 10.1056/NEJMoa2510310
  5. The efficacy and safety of degarelix: a 12-month, comparative, randomized, open-label, parallel-group phase III study in patients with prostate cancer.BJU international / 2008 DecPMID 19035858 / DOI 10.1111/j.1464-410X.2008.08183.x

CLINICALTRIALS.GOV / FOUND RECORDS

  1. Leuprolide Acetate 3.75 mg Depot Injection for Patients With Advanced Prostate CancerCOMPLETED / PHASE3 / Bharat Serums and Vaccines LimitedNCT04914195 / DIRECT intervention MATCH: Leuprolide
  2. Gene Expression Profile After Gonadotropin Releasing Hormone (GnRH) Agonist Trigger of Oocyte MaturationTERMINATED / PHASE4 / UConn HealthNCT01606709 / DIRECT intervention MATCH: Leuprolide
  3. Leuprolide and Goserelin for Ovarian Function Suppression in Pre- or Peri-menopausal Women With Breast Cancer, OFS TrialRECRUITING / PHASE2 / University of Michigan Rogel Cancer CenterNCT07158021 / DIRECT intervention MATCH: Leuprolide
  4. Comparing the Safety and Efficacy in the Use of Hormonal Therapy on Endometriosis Patients After Conservative SurgeryCOMPLETED / PHASE3 / Universitas DiponegoroNCT06145438 / DIRECT intervention MATCH: Leuprolide
  5. Trial of Radiotherapy With Leuprolide and Enzalutamide in High Risk Prostate CancerTERMINATED / PHASE2 / University of California, San FranciscoNCT02508636 / DIRECT intervention MATCH: Leuprolide

Related compounds

RM-NBS

Kisspeptin-10

Read entry →
RM-NBS

Oxytocin

Read entry →